Charles R. Carter
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Charles R. Carter
Earlier roles on record: CFO at Cero Therapeutics Holdings, Inc. (CERO) until September 30, 2024 and CFO at Cero Therapeutics Holdings, Inc. (CERO) until September 25, 2024. Cero Therapeutics Holdings, Inc. reported in an 8-K filed October 2, 2024 that Charles R. Carter resigned as Chief Financial Officer, effective September 30, 2024. Cero Therapeutics Holdings, Inc. reported in an 8-K filed September 25, 2024 that Charles R. Carter resigned as Chief Financial Officer. The proxy statement of Cero Therapeutics Holdings, Inc. reports total compensation of $690,262 for Charles R. Carter in fiscal 2024, including a base salary of $218,750.
“As previously announced, Charles R. Carter resigned from his position as Chief Financial Officer, effective on September 30, 2024.”
“Both Charles Carter, CERo’s Chief Financial Officer, and Daniel Corey, M.D., Chief Technology Officer have also elected to step down from their positions and board seat in the case of Dr. Corey.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2024-09-30
-
Start not stated–2024-09-25
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Cero Therapeutics Holdings, Inc. (CERO) | Former Chief Financial Officer Andrew “Al” Kucharchuk | $218,750 | $690,262 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.